As we usher in the new year, it’s time to position your investment portfolio for a recovery from the devastating pandemic last year.
Browsing: Growth Stocks
The world and the demands of consumers are changing rapidly. In this article, I identify some investable technology trends and companies that could benefit.
These three growth stocks can provide rocket fuel for your portfolio’s growth.
Looking for Hong Kong stocks with good growth potential? Here are three you can consider adding to your watchlist.
Here are three stocks I would buy if I had S$30,000 to allocate.
Here are three promising companies to start you off the new year.
Advertising tech giants, Facebook and Google, are facing increasing competition even as they battle antitrust allegations. Here are 3 companies that are giving them a run for their money.
If you’re looking for growth this year, look no farther than these three stocks.
Some might criticise multi-billionaire Musk for biting off more than he can chew and having his finger in too many pies.
When choosing a company to invest in, the first thing we may filter for is a low valuation multiple. But that may be too simplistic…
A closer look at the biggest components of this exciting new ETF.
Forget about technology stocks, here are three leading US consumer stocks you need to put in your investment watchlist right now.
These companies are offering higher dividends during uncertain times.
We check in once again with the Malaysian glove maker.
Even amid a crisis, these three companies have found suitable acquisitions to grow their business further.
These five companies have delivered stellar performances for investors despite the pandemic.
As the adoption of cryptocurrencies becomes more mainstream, here are 3 growth stocks that will profit from the trend.
The healthcare glove manufacturer continues to announce amazing numbers.
The financial technology company has failed in its bid to win a digital banking licence.
Moderna and BioNTech’s share prices have increased by 621% and 237% year-to-date. Is it too late to get in on these COVID-19 vaccine frontrunners?